These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37029281)

  • 1. Identification of a 1, 8-naphthyridine-containing compound endowed with the inhibition of p53-MDM2/X interaction signaling: a computational perspective.
    Olukunle OF; Olowosoke CB; Khalid A; Oke GA; Omoboyede V; Umar HI; Ibrahim O; Adeboboye CF; Iwaloye O; Olawale F; Adedeji AA; Bello T; Alabere HO; Chukwuemeka PO
    Mol Divers; 2024 Jun; 28(3):1109-1127. PubMed ID: 37029281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach.
    Li K; Hu W; Wang Y; Chen W; Wen H; Liu J; Li W; Wang B
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2288810. PubMed ID: 38059334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction.
    Rasafar N; Barzegar A; Mehdizadeh Aghdam E
    Life Sci; 2020 Mar; 245():117358. PubMed ID: 32001262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
    Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
    Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
    Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
    Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
    J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
    Chen J; Wang J; Zhang Q; Chen K; Zhu W
    Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
    Zhao X; Xiong D; Luo S; Duan L
    Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational-based drug design of novel small molecules targeting p53-MDMX interaction.
    Egbemhenghe AU; Aderemi OE; Omotara BS; Akhimien FI; Osabuohien FO; Adedapo HA; Temionu OR; Egejuru WA; Ajala CF; Ihunanya MF; Oluwafemi OO; Onu CFD; Ajibare AC; Ddamulira C; Abalum JO; Afolayan OM
    J Biomol Struct Dyn; 2024 Aug; 42(13):6678-6687. PubMed ID: 37578044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
    Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
    J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of the first small molecule inhibitor of MDMX.
    Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
    J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.